The Motley Fool Previous Page

Why The Medicines Co. May Be About to Take Off

Seth Jayson
January 12, 2012

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It’s a part of my standard diligence when searching for the market's best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.

Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at The Medicines Co. (Nasdaq: MDCO  ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Medicines doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 12.4%, and inventory increased 2.7%. Over the sequential quarterly period, the trend looks OK but not great. Revenue grew 1.0%, and inventory grew 4.3%.

Advanced inventory
I don’t stop my checkup there, because the type of inventory can matter even more than the overall quantity